NEOGENOMICS INC — Director's Dealing 2018

Oct 25, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2018-10-22

Reporting Person: BRODIE STEVEN G. (VP - Pharma Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-22	Common Stock	M	13334	$3.45	Acquired	45953	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-22	Stock Option (Right to Buy)	$3.45	M	13334	Disposed	2019-03-05	Common Stock (13334.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.52	2022-04-28	Common Stock (50000.0)	50000	Direct
Stock Option (Right to Buy)	$7.15	2021-04-20	Common Stock (100000.0)	100000	Direct
Stock Option (Right to Buy)	$4.78	2020-05-04	Common Stock (120000.0)	120000	Direct
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (58000.0)	58000	Direct

Footnotes

F1: On April 28, 2017, Dr. Brodie was granted 50,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.

F2: On April 20, 2016, Dr. Brodie was granted 100,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F3: On May 4, 2015 Dr, Brodie was granted 120,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.

F4: On February 26, 2018, Dr. Brodie was granted 58,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.